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ABSTRACT
Excess production of Reactive Oxygen Species (ROS), which can be caused by
radiation, cigarette smoke, and pollutants, can cause many damaging cellular effects,
such as DNA damage and unregulated cell apoptosis. If left unmitigated, chronic
overproduction of ROS has been linked to the formation of cancer, diabetes,
atherosclerosis, rheumatoid arthritis, chronic inflammation, Parkinson’s disease,
Alzheimer’s disease, multiple sclerosis, and amyotrophic lateral sclerosis. ROS is
typically eliminated with antioxidants, which scavenge and inhibit the formation of ROS
by becoming oxidized by the ROS and by binding to its precursors.
Curcumin is an effective lipid-soluble antioxidant agent. However, its poor
bioavailability, rapid metabolism by the liver and intestinal tract, and short biological
half-life greatly hinders its therapeutic abilities. The water soluble antioxidant, n-2mercaptoproprionyl glycine (N-MPG), also has been found to scavenge ROS and
decrease lipid peroxidation. Like curcumin, its therapeutic efficacy is limited due to its
poor half-life. In order to improve bioavailability and stability of these two antioxidants,
lipid vesicle formulations have been designed and characterized for transdermal delivery
of the antioxidants. Transdermal delivery is a pain-free method of drug delivery that
allows the antioxidants to permeate through the skin layers for systemic delivery.
Three lipid vesicle formulations, traditional liposomes, ultradeformable liposomes,
and ethosomes, have been fabricated and characterized in order to determine which
vesicle type has the highest skin permeation through the stratum corneum. Each of the
three lipid vesicle formulations were composed of 10 mg/ml Soy-PC, 0.48 mg/ml
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curcumin, and 1 mg/ml N-MPG. The ultradeformable vesicles incorporate an edge
activator, 1.5 mg/ml cholic acid, into its structure to increase deformability of the
vesicles. The ethosomes are vesicles composed in a 40% ethanol solution to increase the
fluidity of the vesicles and skin membrane. The vesicles were characterized for size,
stability, morphology, and entrapment efficiency. A modified Franz-Diffusion Chamber
was used to test the skin permeability of each vesicle type.
Each particle type was fabricated to have a diameter less than 200 nm. The unloaded
particle types were tested for stability using a PeroxiDetect Assay, which detected
amount of lipid hydroperoxides. The ethosomes had the least amount while the
ultradeformable liposomes had the most. However, when analyzing size of the vesicles
over various time points, the ultradeformable liposomes were the most stable. Every
vesicle type had a semi-spherical morphology, with the ultradeformable liposomes
having the smoothest morphology. The ethosomes had the highest entrapment efficiency
of curcumin (statistically similar to the traditional liposomes) and N-MPG.
The modified Franz-Diffusion chamber was used to characterize skin deposition of
the vesicles. At hour 2, the ethosomes had the highest fluorescence and consequently,
skin deposition. At hour 24, the traditional liposomes, which were statistically similar to
the ultradeformable liposomes, had the highest skin deposition. In the image analysis, the
ethosomes had the highest sum intensity in the stratum corneum. In the epidermis, the
traditional liposomes, which were statistically similar to the ethosomes, had the highest
sum intensity. The traditional liposomes had the highest sum intensity in the dermis layer.
Subsequently, the ethosomes are recommended for short-term applications of curcumin
and N-MPG while the traditional liposomes are recommended for long-term applications.
vii
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I. INTRODUCTION

A. Background
Various cellular processes produce reactive oxygen species (ROS), an oxygen
containing molecule with an unpaired electron in its outer orbit [1]. The most commonly
produced cellular ROS molecules are hydroxyl (OH•) and superoxide (O2- •) [1]. These
species can be endogenously formed through cellular respiration, respiratory burst, and
enzymatic reactions. Exogenous production of ROS can occur via exposure to radiation,
pollutants, cigarette smoke, food, and drugs [2]. Ionizing radiation creates ROS by
radiolysis of water or other oxygen containing molecules [2]. Pollutants and cigarette
smoke contain many highly reactive chemicals, leading to the generation of free radicals
and ROS. Various food molecules, such as Fe2+, trans fatty acids, phenols, and alcohols,
can either destabilize chemical reactions to produce ROS or create free radicals upon
chemical breakdown [2]. The introduction of drugs into the system, for treatments like
glucocorticoid therapy or volatile anesthetics for surgery, can stimulate oxidative stress,
forming ROS [2].

FIGURE 1 –Sources of ROS. [2]
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ROS plays a role in many vital physiological processes, including phagocytosis,
apoptosis, cell signaling, and wound healing [2]. However, an excess of ROS can lead to
the degeneration of important biomolecules, such as nucleic acids, proteins, lipids, and
carbohydrates. This excess of ROS can subsequently lead to inactivation of target
molecules, cause DNA damage, and stimulate apoptosis in cells [2]. Chronic
overproduction of ROS has been found to lead to the formation of many debilitating
diseases, such as cancer, diabetes, atherosclerosis, rheumatoid arthritis, chronic
inflammation, Parkinson’s disease, Alzheimer’s disease, multiple sclerosis, and
amyotrophic lateral sclerosis [1].

FIGURE 2 –Oxidative stress and human diseases. [1]

The body naturally eliminates ROS by utilizing ROS scavenging compounds,
called antioxidants. The antioxidant defense system is the body’s way of using enzymatic
or non-enzymatic methods for eliminating and preventing ROS production. A type of
natural enzymatic antioxidants are superoxide dismutases. One function of these enzymes
is to scavenge uncharged H2O2 as it crosses mitochondrial membranes [2]. Thioredoxin is
an important non-enzymatic antioxidant that regulates redox-sensitive proteins by
16

inhibiting ROS interactions [2]. Overall, antioxidants have the ability to oxidize or
reduce ROS, bind to ROS precursors, inhibit the formation of ROS, and bind to metal
ions that subsequently catalyze ROS formation [1][2]. Despite the presence of
endogenously formed antioxidants in the body, supplemental dietary antioxidants, such as
vitamin C, vitamin E, vitamin A, and glutathione, are essential for ROS regulation [2]. A
balance of natural and supplemental antioxidants are needed to effectively remove ROS
from the physiological system. If ROS production is unmitigated due to insufficient
antioxidant quantities, subsequent cellular and tissue damage may occur.

B. Antioxidants
1. Curcumin
Curcumin, also called diferuloyl methane, is a pigment found in turmeric that
exhibits anti-inflammatory and antioxidant properties [3]. Clinical trials involving high
doses of curcumin has shown that it is safe, nontoxic, inexpensive, and therapeutically
effective for a variety of human diseases [3]. Such diseases include cancer,

FIGURE 3 –Chemical structure of curcumin and its three pathways for scavenging ROS
[4].
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cardiovascular disease, arthritis, atherosclerosis, diabetes, renal conditions, Crohn’s
disease, and many other inflammatory diseases.
In terms of the antioxidant capabilities of curcumin, there are three potential
reaction sites where curcumin can react with and eliminate ROS: a diketone (FIGURE 3
Pathway III) and two phenolic groups (FIGURE 3, Pathways I and II) [5]. As seen in
FIGURE 3 I and II, ROS reacting with the phenolic groups yields a radical that can be
transferred around the phenolic group, leading to radical stabilization and elimination.
When ROS reacts with the carbon in between the diketone groups, like in FIGURE 3 III,
a radical is formed on the center CH2 group which can be further stabilized by
transferring electrons throughout the ketone groups. Curcumin’s ability to transfer
electrons is due to its symmetric structure, beta-diketone, and pi electrons [4][5]. These
properties of curcumin make it an extremely effective antioxidant, because it is able to
stabilize free radicals and prevent them from causing damage to biomolecules and
cellular components. However, despite curcumin’s excellent antioxidant capabilities, its
therapeutic efficacy is limited due to its own various properties: poor intestinal
absorption, rapid metabolism, short biological half-life, and low oral bioavailability [3].
Curcumin has extremely poor oral bioavailability due to its poor intestinal
absorption, rapid metabolism, and rapid systemic elimination [3]. Various characteristics
of curcumin, such as its low water solubility and photosensitivity are thought to hinder its
ability to be absorbed by the intestines [6]. Intestinal pH was found by Berginc et al to
also have an effect on curcumin intestinal permeability. In rat jejunum and Transwell
grown Caco-2 cells, curcumin had a slight increase in permeability under acidic
conditions, though curcumin permeation was still considered very low [7]. Other factors
18

that limit the intestinal absorption of curcumin are the presence of various intestinal
enzymes and transporters, such as P-glycoprotein and nonspecific oxydoreductases, that
metabolize curcumin before reaching systemic circulation [7][6]. Curcumin also has an
extremely short biological half-life, approximately 0.31±0.07 hours in rats [6]. These
characteristics of curcumin in physiological conditions lead to the overall poor
bioavailability of curcumin, rendering this potentially powerful antioxidant essentially
therapeutically ineffective.

2. n-2-mercaptoproprionyl glycine (N-MPG)
N-MPG is an aminothiol compound with the ability to scavenge ROS and
decrease radiation-induced lipid peroxidation [8]. It has been proposed for treatments of
various conditions, including cystinuria and protection against ischemia-reperfusion
injury in hypertrophied hearts [8][9]. N-MPG is an effective antioxidant due to its free
thiol group. The free thiol group is able to be oxidized to create a disulfide bridge with
another N-MPG molecule, forming disulfide dimers [8]. Despite N-MPG’s antioxidant
capabilities, N-MPG has limited therapeutic efficacy due to its poor half-life. In
physiological conditions, N-MPG only has a relative half-life of 1-2 hours [10].

FIGURE 4 –Chemical structure of N-MPG [11]
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3. Current Delivery Methods
Various alterations have been made to improve the bioavailability and stability of
curcumin and N-MPG, separately. Nanoparticle formulations, such as liposomes, nanoor micro- emulsions, polymeric nanoparticles, solid lipid nanoparticles, polymer
conjugates, nanocrystals, polymeric micelles, nanogels, and self-assemblies have been
intensely studied for improving the therapeutic efficacy of these antioxidants, separately,
by increasing bioavailability [6] [12] [13]. Most of these modifications have slightly
improved the oral, injection, and transdermal methods for delivering these antioxidants.
The goal of this paper is to investigate a method for delivering these antioxidants,
combined, using transdermal delivery.

C. Transdermal Drug Delivery
Transdermal drug delivery is the systemic administration of therapeutic agents by
penetrating them through the skin. This method of drug delivery is beneficial for
therapeutic agents, such as curcumin, that are easily degraded by the gastro-intestinal
tract and/or undergo the first-pass effect of the liver [14]. When orally administered,
curcumin is usually degraded and unabsorbed by the small intestine, rendering oral
delivery of curcumin ineffective. Transdermal delivery of curcumin will allow curcumin
to reach systemic circulation without having to enter the hostile environment of the
gastro-intestinal tract. Therefore, transdermal delivery of curcumin has the potential to be
more therapeutically effective compared to oral drug delivery of curcumin. Another
common method for administering curcumin and N-MPG is through needle injections,
which are painful and require frequent needle sticks due to fast drug-clearance [14].
20

Needle injections also have the potential to result in wound site infection, which could
subsequently lead to sepsis. It also generates dangerous medical waste and can increase
risk of disease transmission if needles are improperly disposed of [15]. Due to the
painfulness of the injection method of drug delivery, it also typically has low patient
compliance. Transdermal delivery does not require frequent injections, allowing for a
controlled and infection-free delivery of curcumin and N-MPG. Overall, transdermal
delivery of curcumin and N-MPG has the potential to increase the systemic
administration of these therapeutic agents in a controlled, non-invasive fashion.
The main hindrance for transdermal delivery is penetration of the agent(s) through
the skin to reach dermal capillaries. Human skin is composed of three main layers:
epidermis, dermis, and subcutaneous [15]. The stratum corneum is the outermost layer of
the epidermis and is the main barrier to successful transdermal delivery [15]. The stratum
corneum is commonly compared to a brick wall, with the bricks being the keratin-rich
corneocytes and the mortar being the intercellular lipid lamella [15]. The intercellular
lipid lamella is in a highly organized crystalline structure and is an essential component
for the barrier properties of the stratum corneum [15]. The other layers of the epidermis
(stratum lucidium, stratum granulosum, stratum spinosum, stratum basale) also provide
hindrance for further permeation. Ultimately, the target layer of the skin for transdermal
drug delivery is the dermis. This layer of the skin contains small capillary vessels;
therefore, if the drug reaches this layer, the drug can potentially enter the capillaries and
reach systemic circulation [15]. However in the dermis, capillary hydrostatic pressure,
lymphatic uptake, and endothelial permeability can provide physical barriers for systemic
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absorption of the drug. As a first step for transdermal delivery of curcumin and N-MPG,
this work focuses on their permeation through the stratum corneum.

FIGURE 5 –H&E stain of skin, illustrating its layers [14].

D. Lipid Vesicles
1. Traditional Liposomes
One method to penetrate curcumin and N-MPG through the stratum corneum,
utilizes lipid vesicles, or liposomes. Liposomes are essentially phospholipids that have
aggregated in a lipid bilayer(s) to enclose an aqueous medium. Therefore, liposomes have
the ability to contain lipophilic drugs in their lipid bilayer, such as curcumin, and
hydrophilic drugs in the encapsulated aqueous medium, such as N-MPG (see FIGURE 6)
[15]. Because the cell membrane of human cells is composed of a phospholipid bilayer,
liposomes can be formed that are non-toxic, biodegradable, and a natural permeation
enhancer [15]. The lipid composition also helps to increase the bioavailability by
protecting the drug from degradation. Liposomes also have the ability to increase the
22

stability of the encapsulated drug, which is essential for delivering curcumin and N-MPG
because of their short half-lives [6][10]. Liposomes also have the potential to provide a
sustained/controlled release of the drug [15]. After skin permeation to the dermal layer,
the liposome must pass through capillary endothelial cells to reach systemic circulation.
During systemic circulation, the liposome will have to circumnavigate phagocytic cells to
ultimately undergo endocytosis with target cells.

N-MPG

FIGURE 6- Schematic of Liposome containing curcumin and N-MPG

Over the years, modifications have been made to liposomes to increase the
efficacy of their transdermal delivery. One modification was to add a non-ionic
amphiphile surfactant to the composition of the vesicles, forming a new type of vesicle
called niosomes [15]. These vesicles improved penetration, but not into the deeper skin
tissues. However, with the development of ultradeformable liposomes and ethosomes, by
Cevc et al and Touitou et al respectively, vesicle penetration through the stratum corneum
and into the deeper layers of the skin improved drastically [15]. Ultradeformable
liposomes are liposomes that also contain an edge activator in their lipid bilayer, while
ethosomes are liposomes that are made in an ethanol/water solution.
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A common method for liposomal fabrication is called the mechanical-dispersion
method. This method involves dissolving the lipids in a solvent, typically chloroform.
The lipids are then dried down by evaporating off the solvent. This leaves a film of lipids
on the container, which is then rehydrated in a buffer solution at 370C for an hour. Probe
sonication can then be used to break apart the lipids, causing them to aggregate into a
smaller lipid vesicle. Verma et al, 2002 found that vesicle sizes of 120 nm compared to
191 nm, 377 nm, and 810 nm had more vesicle permeation through the stratum corneum
and into the deeper skin layers [17]. Therefore, the main criterion established for particle
fabrication was to develop particles less than 200 nm, in order to allow for particle
migration through the skin during transdermal delivery [17].
2. Ultradeformable Liposomes
Ultradeformable liposomes are hydrophilic lipid vesicles composed of
phospholipids and a single chain surfactant called an edge activator. The phospholipid
typically used in the formation of ultradeformable liposomes are various
phosphatidylcholines, either soya or egg phosphatidylcholine [15] [18]. Potential edge
activators include cholic acid; span 60, 65, or 80; and tween 20, 60, or 80 [15][18]. The
addition of the edge activator to the liposome composition increases the deformability of
the vesicles, allowing them to squeeze through the channels in the stratum corneum [18].
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FIGURE 7 – Conventional versus Ultradeformable vesicle moving through the stratum
corneum [18].

The main mechanism behind increased penetration of ultradeformable liposomes
is the osmotic gradient of the skin. [15]. Dry skin at the surface of the skin is
approximately 20% water, while the underlying epidermis is approximately 100% water
[15][18]. This gradient drives the ultradeformable liposomes movement through the
brick-walls of the stratum corneum.

20% Water- High Osmolarity

100% Water- Low Osmolarity

FIGURE 8 – Osmotic gradient of skin, and subsequent movement of ultradeformable
liposome [15].
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The main method for producing ultradeformable liposomes is the mechanicaldispersion method described under Traditional Liposomes. The only difference is that
during the hydration phase of vesicle formation, the lipids are hydrated for 15 minutes at
430C and then placed in 2-80C for an hour [15]. The vesicles reach their maximum
hydrodynamic radius at the colder temperature and are later reduced in size with
processes such as probe sonication, freeze-thaw, and reverse evaporation [15].
3. Ethosomes
Ethosomes are lipid vesicles composed of phospholipids, a high concentration of
ethanol, and water. The typical phospholipids used are either soya phosphatidylcholine
(Soy-PC) or egg phosphatidylcholine. The ethanol concentration ranges from 20-45% in
water. Other potential additives include a polyglycol and cholesterol to increase skin
permeation and increase vesicle stability [15][19]. Typically, the ethosomes made with a
higher ethanol concentration yielded smaller vesicle diameters and had increased skin
permeation [15].

FIGURE 9 –Ethosome particle [19].

Due to the high concentration of ethanol, ethosomes typically have a very high
encapsulation efficiency of hydrophilic and lipophilic molecules [15]. It also increases
the fluidity of the vesicles, as well as the fluidity of the skin layers. The ethanol works to
26

solubilize the lipid lamella, creating defects in the lipid lamella the fluidic vesicles are
then able to maneuver through [15][19].

FIGURE 10 –Schematic of Ethosome movement through skin [20]

Two commonly used methods for fabricating ethosomes include the mechanicaldispersion method and the cold method. The mechanical dispersion method is similar to
the process described in the Traditional Liposomes section, except ethanol is incorporated
into the buffer (20-45%) [19]. The cold method involved dissolving the lipids in ethanol,
heating this lipid-ethanol solution and heating water to 300C, and then mixing the two
solutions together with stirring [19]. The lipid vesicles can then be reduced in size
through probe sonication.
4. Previous Study
Previously, fusogenic liposomes were developed by this group using the lipid to
N-MPG to curcumin ratio 10:1:0.48 (mg/ml) for the purpose of injection delivery.
Curcumin was trapped inside the lipid bilayer while N-MPG was encapsulated inside the
aqueous medium of the lipid vesicle. Despite the potential of these fusogenic liposomes,
the required intravenous injection of this therapy was deemed undesirable. Therefore, an
alternative method for delivery of curcumin and N-MPG was sought after.
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E. Hypothesis and Specific Aims
Lipid vesicles containing the antioxidants curcumin and N-MPG can be modified
to permeate these therapeutic agents passed the stratum corneum of the skin. To address
this hypothesis, these aims were specified:
1. Fabrication of traditional liposomes, ultradeformable liposomes, and
ethosomes containing the antioxidants curcumin and N-MPG that are less
than 200 nm in diameter.
2. Characterization of each vesicle for stability, morphology, and entrapment
efficiency in order to compare vesicle types.
3. Investigation of the transdermal delivery potential of each type of vesicle

using pig skin.
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II. METHODS

A. Vesicle Fabrication
Using the fusogenic liposomal compositions previously developed by our
group, the composition of the traditional liposomes was 10 mg/ml Soy-PC, 1 mg/ml NMPG, and 0.48 mg/ml curcumin, in a PBS solution. The Soy-PC, specifically
Phospholipon 90G (Lipoid, Ludwigshafen, Germany), contains 95% soyphosphatidylcholine, 2% lyso-phosphatidylcholine, 2% fatty acids, and other lipid soluble
substances (See FIGURE 11) [21]. The traditional liposomes were fabricated using the
mechanical-dispersion method. In this method, 250 mg of Soy-PC (95%) was dissolved
in 1 ml of chloroform and 200 µl of this solution was added to a test tube. Next, 50 mg of
curcumin (Sabinsa) was dissolved in 2.5 ml of acetone and 120 µl of this solution was
added to the test tube. The solvents were then evaporated off using a steady stream of
nitrogen gas, leaving a lipid residue. The lipid residue, or thin film, was then placed
under vacuum (Thermo, Air Cadet) for 24 hours in order to completely remove any
remaining solvents.

FIGURE 11 –Chemical structure of Soy-PC [21]
The lipid residue was then rehydrated by adding 5 ml of a 1 mg/ml N-MPG in
PBS solution with a pH of 7.4. Two 5 mm glass beads (Sigma) were added to the test
tube and it was covered with parafilm. The tube was then vortexed for 15 seconds and
placed in a 37oC water bath for one hour, being vortexed every 15 minutes for 15
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seconds. The contents of the tube are then removed and placed in a 15 ml centrifuge tube
for probe sonication (Branson, Sonifer 450). Probe sonication was performed with a
booster horn and micro-tip probe using a duty cycle of 60% and an output control of 7,
for five minutes. During sonication, the samples were placed in an ice water bath (16oC18oC) with the probe placed in the middle of the centrifuge tube and far down to where
the centrifuge tube begins to become conical. The solution was then centrifuged with a
Beckman TJ-6 at the max speed of 10,000 rpm to remove titanium particles form the
sonicator tip. The supernatant was then removed for particle size analysis using a Protein
Solutions DynaPro DLS (Wyatt Instruments, Santa Barbara, CA). Samples were stored at
4oC and protected from light.
The ultradeformable liposomes composition was determined to be 10 mg/ml SoyPC, 1 mg/ml N-MPG, 0.48 mg/ml curcumin, and 1.5 mg/ml cholic acid (Sigma), in a
PBS solution [22]. Patel et al similarly developed curcumin loaded transfersomes,
suggesting a lipid to span 80 ratio of 85:15 (in mmol) for optimal skin permeability of
curcumin [22]. Span 80, tween 20, and tween 80 were initially attempted for
ultradeformable liposome fabrication using that lipid to edge activator ratio. Cholic Acid
was ultimately chosen because compared to the previously mentioned edge activators, it
created a thin film of lipids, curcumin, and edge activator during fabrication.
For the fabrication of the ultradeformable liposomes, the mechanical-dispersion
methods previously described to make the traditional liposomes was utilized with slight
modifications. During the drying down phase, 167µL of a 45 mg/ml cholic acid (45 mg
cholic acid dissolved in 1 mL EtOH) was added to the test tube with the Soy-PC and
curcumin. The solvents were evaporated and the resulting lipid residue was placed under
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vacuum, like previously described. During the hydration phase, instead of placing the test
tube in a 370C water bath for one hour, it was placed in a 430C water bath for 15 minutes
and then a 2-80C refrigerator for 1 hour. The tube was vortexed for 15 seconds every 15
minutes. The sonication, centrifugation, sonication, DLS and storage parameters
remained the same as those described for the traditional liposomes fabrication.
For the ethosomes, the initial fabrication technique utilized was the mechanicaldispersion method described to make the traditional liposomes. The only difference was
the lipid residue was hydrated in an ethanol solution. To determine what ethanol
concentration would yield an appropriate vesicle diameter less than 200 nm, 1 mg/ml
Soy-PC ethosomes in 15%, 30%, 45%, and 70% ethanol solutions were fabricated. A
40% ethanol solution containing 16.24 mg/ml of Hank’s Balanced Salt Solution (HBSS)
(Sigma, St. Louis, MO) and 1.33 mg/ml of Trizma base (Sigma) was chosen for future
ethosome studies. The Soy-PC concentration was increased to 10 mg/ml so the
ethosomes could be directly compared to the other liposome configurations. The probe
sonicator duty cycle, or the length of each sonication pulse, was varied between 90%,
75%, and 60% duty cycle to determine which setting would yield a smaller vesicle
diameter. The 60% duty cycle was found to yield the smaller vesicle diameter. Next, the
cold method for ethosome fabrication was tested and found to yield smaller particle sizes
compared to those made using the mechanical-dispersion methods. Finally, particles were
sterile filtered (0.2 µm) after fabrication, yielding particles with a diameter less than 200
nm.
Thus for characterization and transdermal studies, the fabrication method used
was the cold method with sterile filtering. For the cold method, 50 mg of Soy-PC
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(Lipoid) and 2.4 mg of curcumin were dissolved in 2 ml of ethanol in a closed container,
with stirring. This container was then heated up to 30oC for 15 minutes in a water bath.
Another solution containing 16.24 mg/ml of HBSS (Sigma) and 1.33 mg/ml of Trizma
base (Sigma) was also heated up to 30oC for 15 minutes in a water bath. Three ml of the
HBSS and Trizma base solution and 5 mg of N-MPG were added to the Soy PC,
curcumin, and ethanol solution. This combination was then stirred for 5 minutes and
placed in a 15 ml centrifuge tube. The pH of the solution was adjusted to 7.4. The sample
was sonicated (Branson, Sonifer 450) and centrifuged (Beckman TJ-6) using the same
settings as those used for the traditional and ultradeformable liposomes. The supernatant
was removed carefully and then sterile filtered through a 0.2 µm syringe sterile filter into
a 15 ml centrifuge tube. The size of the particles were then analyzed using DLS. The
samples were then stored at 4oC and protected from light.
Dynamic Light Scattering (DLS) analysis was used to ensure the particle sizes
were less than 200 nm (n=6 per vesicle type. The software package utilized with the DLS
was Dynamics V6. A model for globular proteins was used to model the particle type,
and based on the autocorrelation of the intensity during measurement which can be used
to determine the radius of the particles [23]. The solvent setting used to analyze the
traditional and ultradeformable liposomes was PBS, while the solvent setting used for the
ethosomes was 20% Ethanol. Fifty readings were taken for each sample immediately
after the sample was made. The fifty diameter and polydispersity readings were averaged.
The means and standard deviations of these averages were recorded. Polydispersity index
is measure indicating how heterogeneous the sample is. An ANOVA post hoc Tukey test
(α=0.05) was ran to determine which particle types were statistically similar in size and
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polydispersity. Minitab 17 was the software used for all statistical analysis performed in
this paper.

B. Liposome Stability
1. Lipid Peroxidation
The stability of each particle type, without curcumin and N-MPG, was analyzed
using a PeroxiDetect Kit (Sigma). This kit was used to measure the amount of lipid
hydroperoxides, which form from the oxidation of unsaturated fatty acids. First, a 90%
methanol stock solution was created by combining 108 mL methanol and 12 mL water.
The Organic Peroxide Color Reagent was made by adding 120 mL of the 90% methanol
to the kit bottle. To make the Working Color Reagent, a ratio of 100 volumes of Organic
Peroxide Color Reagent stock to one volume of Ferrous Ammonium Sulfate Reagent was
added together. Next, 100 µL of the particle sample being tested was added to a 1.5 mL
cuvette. Then 1 mL of Working Color Reagent was added to the cuvette. The samples
were incubated at room temperature for 30 minutes, protected from light. The absorbance
of the samples was measured with a spectrophotometer (Thermo) at 560nm. A standard
curve plotting lipid hydroperoxides from 0 to 16 nano-moles versus their respective
absorbance was created using tert-butyl hydroperoxide as a positive control without
lipids. This yielded the equation y=0.0408x + 0.0011 with y equaling absorbance and x
equaling nano-moles of lipid hydroperoxides. The r2=0.9976. It was predetermined that
the maximum amount of lipid hydroperoxides was 10 nmoles. The PeroxiDetect Kit was
performed on each particle type at days 0, 3, 7, and 113 post-fabrication. Three samples
from each particle type was assayed three times. The total mean absorbance and standard
33

deviation was used to calculate the mean nano-moles of lipid hydroperoxides and
standard deviation of each particle type. A one-way ANOVA with α=0.05 was used to
determine which particle type minimizes the amount of nano-moles of lipid
hydroperoxides over time. Equal variance was tested prior to running the ANOVA. If
equal variance could be assumed then a Tukey comparison was ran. Otherwise, a GamesHowell comparison was ran.
2. Size Analysis
The stability of each particle type, with curcumin and N-MPG, (n=6) was also
analyzed by taking size measurements using DLS analysis at various time points postfabrication [24]. Time measurements include day 0, 3, 7, 14, and 30, post fabrication as
these days would likely show liposome aggregation or liposome destruction via lipid
peroxidation. The particle type was determined unstable once the mean particle size was
statistically different from day 0 or once the mean particle size had changed a
predetermined percentage. A one-way ANOVA post hoc Tukey (α=0.05) was used to
determine if particle size at each time point differed significantly from day 0. The other
metric for determining particle stability involved taking the 50 measurements from each
particle batch at day 0 and finding the mean and standard deviation for that sample. The
standard deviation percentage of the mean was then found by dividing the standard
deviation by the mean and multiplying by 100. This was then averaged for ethosomes,
traditional liposomes (n=6 for both), or ultradeformable liposomes (n=4) to yield the
criteria for allowable percent change in size. For ethosomes, ultradeformable liposomes,
and traditional liposomes, the allowable percent change is 34.5%, 22.5 %, and 32.8%,
respectively. The percent change in mean particle size from day 0 was found by taking
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the mean particle size at day X subtracted by the mean particle size at day 0, divided by
mean particle size at day 0, and multiplied by 100.

C. Liposome Characterization Using SEM
Scanning Electron Microscopy (SEM) was used to examine the shape and size of the
liposome formulations. In order to visualize the liposomes, 15 µL of the sample was
pipetted onto carbon tape on a copper stub and left to dry for over 12 hours. The samples
were sputter coated with gold/palladium in a 0.1 torr vacuum with a voltage of 1.8 kV for
two minutes. A Zeiss Supra 35VP scanning electron microscope using a secondary
electron detector with an EHT value ranging from 1.50 kV to 3.00 kV was used to
visualize each particle type.

D. Entrapment Efficiency
The entrapment efficiency of curcumin for each lipid vesicle type was determined
using the ultracentrifugation method [25]. A Beckman L8-70M Ultracentrifuge with a
50.4 TI rotor was used to spin down three 1 mL aliquots of each sample (n=3) for 30
minutes at 40,000 rpm. Once finished, the supernatant of each sample was removed. The
supernatant was diluted in PBS, using a 50 to 950 sample to PBS volumetric ratio. A
spectrophotometer (Thermo) read the absorbance at a fixed wavelength of 425 nm. Two
concentration curves were created to determine the amount of curcumin in the
supernatants of the samples. The first concentration curve initially dissolved curcumin in
100% methanol to create a 1 mg/ml solution, because curcumin is extremely insoluble in
water. In order to mimic the solutions used to fabricate the traditional and
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ultradeformable liposomes, subsequent dilutions were performed with a 1 mg/ml N-MPG
in PBS solution. This first concentration curve was graphed from 25 µM to 1000 µM of
curcumin, yielding the equation y=0.003x – 0.0726, r2=0.9771, with y equal to
absorbance and x equal to curcumin concentration. This was then used to determine the
amount of curcumin in the supernatants of the traditional liposome and ultradeformable
lipsome samples. The second concentration curve was created by dissolving and diluting
curcumin in 40% EtOH, in order to mimic the solution of the ethosomes. This second
concentration curve was graphed from 25 µM to 400 µM of curcumin, yielding the
equation y=0.0038x + 0.1802, r2=0.9958 with y equal to absorbance and x equal to
curcumin concentration. This equation was then used to determine the amount of
curcumin in the supernatant of the ethosome samples. Entrapment efficiency was then
calculated as a percent using the equation [25]:

% 𝐸𝑛𝑡𝑟𝑎𝑝𝑚𝑒𝑛𝑡 =

𝐶𝐶𝑀𝑓𝑎𝑏 − 𝐶𝐶𝑀𝑠𝑢𝑝𝑒𝑟𝑛𝑎𝑡𝑎𝑛𝑡
× 100
𝐶𝐶𝑀𝑓𝑎𝑏

The percent entrapment calculations from the three aliquot readings from each individual
particle batch were averaged together. A one-way ANOVA post hoc Tukey test (α=0.05)
was then used to determine if particle type significantly affected entrapment efficiency
and if so, which type had the highest.
A typical method for quantifying the amount of N-MPG in a solution is by using
Ellman’s Reagent to bind to N-MPG’s free thiol group. Once bound, TNB is released and
ionizes to TNB2- in water. TNB2- is a yellow color and can be read at a wavelength of 412
nm on a spectrophotometer. However, this reading is masked by curcumin because it
reads at a wavelength of approximately 425 nm. Therefore, the entrapment efficiency of
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N-MPG by each vesicle type was theoretically calculated using the equation in FIGURE
12.

FIGURE 12 –Schematic of Theoretical Entrapment Efficiency [26]

The entrapment efficiency is a percentage of the inner volume of the vesicle (Vin)
over the total volume of the sample (V) [26]. Inner volume is a function of the radius of
the particle (rin), the bilayer thickness (d), the lipid concentration (c), the amount of lipid
molecules per vesicle (NA), and the exposed area of a single lipid molecule (a). The
calculation is repeated with probability weights (Pi) over a log normal distribution of
vesicle sizes [26]. For each particle type, the bilayer thickness (d) was assumed to be 4.9
nm [26], the mean molecular area of a single lipid molecule (a) was assumed to be 40 Å
[26], the lipid concentration (c) of the sample was10 mg/ml or 12.9 mM, and sample
volume (V) was 5 mL. The particle size and size distribution of each particle type was
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chosen to be the diameter and standard deviation reported in the “Vesicle Fabrication”
section of the results.
E. Skin Permeation
In order to determine if the lipid vesicles were able to penetrate into the dermis layer
of skin, testing was performed using pig skin and a modified Franz diffusion chamber
[26]. The pig skin came from the abdominal region of one year old Yucatan or Yorkshire
pigs immediately after they were sacrificed. Upon excision, the skin was washed with 7.4
pH PBS and stored at 40C for a maximum of two days. Fat and muscle layers were
removed from the skin layers using a scalpel.

FIGURE 13 – Franz Diffusion Chamber [27]

A Franz Diffusion Chamber is an apparatus that allows one to determine the
pharmacokinetics of a transdermal treatments. The typical Franz Diffusion Chamber can
be viewed in FIGURE 13. Compartment 1 is the donor compartment that houses the
treatment being tested [27]. Below this compartment is where the skin is placed.
Compartment 2 houses a warm circulating solution where the sample will travel once it
has migrated through the skin [27]. The traditional Franz Diffusion Chamber was
recreated using a 12 cell well plate and its respective cell culture insert (FIGURE 14).
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FIGURE 14 -12 cell well plate and insert used for modified Franz Diffusion Chamber
[28].

The excised skin was cut into circular pieces using a metal cylinder approximately
10 mm in diameter. The circular skin pieces were then placed into the 12 cell well cell
culture insert with the dermis layer facing downward. The skin was fastened and sealed
to the cell culture insert by placing 20 µL of surgical glue (Vetbond Tissue Adhesive)
around the edges of the skin. Once the glue dried, 1.25 mL of the vesicle treatment was
placed on top of the skin. The cell inserts were placed on white paper for 5 minutes and
analyzed for leakage before being used. A stir bar and 700 µL of PBS-Ascorbic Acid
(100 µL of 1M ascorbic acid/2.9 mL PBS) were placed into each cell well. Then, the skin
cell culture insert with treatment was added to the cell well. Once a 12 cell well plate was
filled with skin cell culture inserts, the top was secured and the cell plate was wrapped in
parafilm and aluminum foil. It was then placed in a 370C room on top of a stir plate.
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FIGURE 15 –Image of cell well insert with skin and treatment, in the 12 cell well plate.

The skin permeation of the three liposome formulations was examined over a 24
hour time period. A Thermoscientific NanoDrop 2000c Spectrophotometer was used to
take absorbance measurements of the solution in the lower chamber at hours 2, 8, 18, and
24. Control treatments include PBS and free curcumin in PBS, while liposome treatments
include drug-loaded ethosomes, ultradeformable liposomes, and traditional liposomes.
Each treatment had a skin-containing cell insert with an n=2. Three absorbance readings
were taken from each cell well by placing 2 µL of the sample onto the NanoDrop reader.
However, the use of the NanoDrop Spectrophotometer was deemed not sensitive enough
to detect the curcumin that permeated the skin.
The skin permeation study was replicated, taking fluorescence measurements
using a fluorometer, (Turner) instead of taking absorbance measurements using the
NanoDrop. A fluorometer was thought to detect lower concentrations of curcumin
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compared to the NanoDrop. A Turner Biosystems Modulus with the Blue LED (465 nm
to 485 nm wavelength) was used to measure Fluorescent Specific Units of the solution
contained in the cell well. 125 µL of the sample was placed in glass microtube and read.
The time points for this study were hours 2, 7, 17, 24, and 41. However, this measure was
also determined not sensitive enough.
Since utilizing the NanoDrop and fluorometer were determined to be ineffective
in measuring lipid vesicle permeation, another measure determining amount of lipid
vesicles deposited in the skin was performed. In this testing, the modified Franz
Diffusion Chamber was set up like previously described. Treatments performed were a
PBS control (n=3) and each lipid vesicle formulation (ethosomes: n=4; ultradeformable
and traditional liposomes: n=3). After 24 hours in the modified Franz Diffusion
Chamber, the Yorkshire pig skin sections were removed from cell culture inserts with a
scalpel and placed in 2 mL centrifuge tube with 1 mL of 200 proof EtOH to extract
curcumin deposited in the skin. The centrifuge tubes were then placed in an ultrasonic
bath (Fisher Scientific FS60) for 1 hr [29]. Three fluorescence readings were then taken
from each sample using the Turner Biosystems fluorometer. Skin deposition was also
determined at hour 2(PBS: n=3; ethosomes: n=4; ultradeformable and traditional
liposomes: n=3). A one-way ANOVA post hoc Tukey (α=0.05) was used to determine if
treatment affected skin deposition and to compare treatments.
The Yorkshire pig skin from the skin permeation study involving the NanoDrop
reader was post-processed. The skin was removed from the cell culture insert with a
scalpel and then placed in 4% formaldehyde for 48 hours. Next, the skin was placed into
a 30% sucrose solution for a minimum of 48 hours or until the tissue sank to the bottom
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of its container. Then, the tissue was embedded in a tissue mold (Peel-A-Way ®) by
freezing the tissue in optimal cutting temperature (Tissue-Tek ®) compound using dry
ice. Once frozen, the tissue block was covered in aluminum foil and stored at -800C. A
cryotome (Thermo Electron Corporation Shandon FSE), with the cryobar -500C, the
chamber -200C, and the specimen -200C, cut the blocks of tissue into 30 µm sections.
Once cut, the sections were placed onto microscope slides. Slides from each treatment
type was used for imaging the curcumin fluorescence in the skin and for histological
staining of the skin.
A hematoxylin and eosin stain (H&E) was performed on the cut skin samples in
order to differentiate the skin layers. First, the microscope slides were heated on a hot
plate at 650C for 20 minutes. Then the tissue was hydrated in DI water for 2 minutes, two
times. The slides were then placed in 0.1% Hematoxylin (Sigma) for 10 minutes. Then
the sections were washed with tap water three times, each for 1 minute. The microscope
slides were then dipped in 0.5% Eosin Y in 95% EtOH (Sigma) for 15 seconds. The eosin
was then washed off twice with DI water. The tissue was dehydrated by placing the slides
in increasing ethanol concentrations: 50%, 70%, 95%, and100%. The microscope slides
were placed in each ethanol solution for two minutes, two times. Then the slides were
placed in xylene for 1 minute before a coverslip was attached with Permount [30]. The
H&E stained slides were then imaged with a digital inverted microscope (Evos xL Core,
Waltham, MA) using a magnification of 40x, a brightness of 84, and a cool color balance.
Three pictures were taken for each treatment. The images were then loaded into the NIS
Elements program in order to measure two lengths: the top of skin to the bottom of
stratum corneum and the bottom of stratum corneum to the bottom of epidermis. Three
42

length measurements were taken for each skin layer in each image by measuring from the
two outer edges and the middle of the skin (see FIGURE 16). These length measurements
were used for fluorescent image analysis.

FIGURE 16 –Example image of length measurements taken of H&E stained tissue.

A confocal microscope (Nikon Eclipse Ti) was used to capture fluorescent images
of the cut skin tissue using NIS Elements software. Since curcumin naturally fluoresces
green when exposed to blue light, any curcumin or curcumin containing particle can be
visualized using fluorescent microscopy. Appropriate sections were found using the
bright field setting. The light source was switched to green fluorescent protein (GFP)
with an excitation wavelength of 488 nm. The control PBS treated skin had brightness
and color automatically adjusted to minimize auto-fluorescence of the tissue. These
settings were then used to image the remainder of the skin treatments. All pictures were
taken on 60x magnification. Three images, bright field and GFP, were taken per
treatment.
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To analyze the fluorescent images, the skin layer lengths determined from the
H&E stain were used. Three boxes, each a 35 X 35 µpixels, were drawn per skin layer
per image. They were randomly placed in each skin layer by using the lengths found from
the H&E stain. Another box was drawn outside of the skin to determine background
noise. The boxes were then analyzed to find the sum intensity of each box. The sum
intensity of the background box was subtracted from the other box measurements taken
from that image to remove the noise. This was done for each treatment: PBS, free
curcumin in PBS (control treatment), ethosomes, ultradeformable liposomes, and
traditional liposomes. The sum intensity from the PBS condition was averaged for each
skin layer. These averages were then subtracted from the sum intensities found for the
other treatments in order to remove natural skin fluorescence from their measurements.
Therefore, any excess fluorescence found in the skin layers is from the curcumin in the
treatments. A one-way ANOVA post hoc Tukey (α=0.05) was performed for each skin
layer-- stratum corneum, epidermis, and dermis-- to determine if treatment affects Sum
Intensity and if so, which treatment corresponds to the highest fluorescence in the skin
layer.

FIGURE 17 –Example image of Sum Intensity measurement.
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III. RESULTS

A. Vesicle Fabrication
In order to fabricate the traditional liposomes, the common mechanical-dispersion
method was chosen for its ease of use. Soy-PC was utilized as the bilayer forming lipid in
all particle formulations because it is commonly used in the development of
ultradeformable liposomes and ethosomes [15][18]. This lipid and the concentration of 10
mg/ml Soy-PC was kept consistent across all particle types, so the additives that caused
varying particle characteristics could be pinpointed.
The mechanical-dispersion method was utilized during the fabrication of the
ultradeformable liposomes. Initially, the ultradeformable liposomes were made using
span 80 as the edge activator. However, during the drying down phase of fabrication, the
solvent of the span 80 would not evaporate, yielding a viscous solution containing trace
amounts of chloroform and acetone. Tween 20 and tween 80 were also attempted to be
used as an edge activator yielding similar results. Therefore, the lipid residue could not be
created with these surfactants, preventing further fabrication. Cholic acid was then tried
with successful results, rendering it the edge activator of choice.
The original method used for ethosome fabrication was the mechanical dispersion
method. The concentration of ethanol to be used for the hydrating solution was tested by
making the particles in various ethanol concentrations. A high ethanol concentration is
desired, because it typically leads to increased skin permeation [19]. For these trials, a
lipid concentration of 1 mg/ml Soy-PC was utilized because only the trends were sought
after.
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FIGURE 18 – Effect of ethanol concentration on size of ethosomes (n=1)

Contrary to literature findings, the higher ethanol concentrations yielded larger
vesicle diameters [19]. Therefore, in order to decrease the vesicle diameter and still
maintain a high ethanol concentration, a 40% ethanol, 16.24 mg/ml HBSS (Sigma), and
1.33 mg/ml Trizma base (Sigma) solution was chosen to make future ethosomes. The
HBSS and Trizma base were added to the ethanol solution as buffers.
Since the size of the ethosomes remained greater than 200 nm, the sonication duty
cycle was varied to determine the optimal duty cycle setting. The duty cycle determines
the length of each sonication pulse. Sonication introduces a high amount of sound energy
into the solution, causing the lipids to rearrange into smaller vesicles. However, this high
energy can also cause the generation of lipid hydroperoxides, leading to instability and
ultimate degradation of the vesicles. The desired duty cycle setting is low, while still
creating small vesicle sizes. The sonication duty cycle chosen was 60%, because it was
lower and yielded particle sizes comparable to the 75% and 90% duty cycles.
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FIGURE 19 –Effect of probe sonicator duty cycle on ethosome size (n=1)

Next, the cold method for ethosome fabrication was attempted to lower particle
size. After running the particles through a 0.2 µm syringe sterile filter, the particles
decreased to a diameter below 200 nm. Therefore, the cold method, 40% ethanol, a duty
cycle of 60%, and a sterile filter were used for ethosome fabrication for all subsequent
studies. These parameters were only examined with the ethosomes because the vesicle

Particle Diameter (nm)

types were inherently less than 200 nm, unlike the ethosomes.

Cold vs Mechancial-Dispersion Method:
Ethosome Fabrication
800
600
400
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Cold+Sterile Filter

Fabrication Method

FIGURE 20 –Effect of fabrication technique on ethosome size n=1. Graphed
with standard error of mean.
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Ideal particle sizes are less than 200 nm for vesicle skin permeation [17]. In order
to ensure particle sizes were below this value, DLS analysis was performed on each
particle type (n=6). Fifty measurements were performed for each reading. Size
measurements and polydispersity are reported in TABLE 1. Liposome type was found to
statistically affect particle size (p=0.015) and polydispersity (p=0.030). The ethosomes
and ultradeformable liposomes were found to be statistically different in particle size
(p=0.012) while the ethosomes and traditional liposomes were statistically different in
polydispersity (p=0.028).
TABLE I
MEAN PARTICLE DIAMETER AND POLYDISPERSITY
Particle Type
Traditional
Liposomes
Ultradeformable
Liposomes
Ethosomes

Diameter mean (nm) ±
standard deviation (nm)
127.43 ± 16.22

Polydispersity mean (%) ±
standard deviation (%)
47.92 ± 10.84*

81.63 ± 18.22*

55.93 ± 24.06

106.50 ± 33.17*

75.70 ± 11.17*

*denotes statistically different.

In conclusion, all vesicle types were made with 10 mg/ml Soy PC, 0.48 mg/ml
curcumin, and 1 mg/ml N-MPG. The traditional liposomes and ultradeformable
liposomes were made using the mechanical-dispersion method. The ultradeformable
liposomes also contained 1.5 mg/ml cholic acid. These two particle types were easily less
than 200 nm in size. In order to make the ethosomes less than 200 nm in size, they had to
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be fabricated using the cold method, 40% ethanol, a sonication duty cycle of 60%, and
sterile filtered.
B. Liposome Stability
1. Lipid Peroxidation
The lipid peroxidation of the non-drug loaded particles was analyzed using a
PeroxiDetect Kit (Sigma) (FIGURE 21). This kit detects the amount of lipid
hydroperoxides in a sample. Once lipid hydroperoxides form, they propagate throughout
the sample causing the lipid vesicles to degrade. The antioxidants in the drug-loaded
particles can quench lipid hydroperoxides; however, this limits their therapeutic
effectiveness. Therefore, understanding when the lipid hydroperoxides start to form is
important for determining vesicle stability and efficacy. The PeroxiDetect Assay was
performed on days 0, 3, 7, and 113 on each vesicle type. Three samples from each
particle type was assayed three times.
A one-way ANOVA post hoc Tukey test (α=0.05) was performed to determine
which particle type minimizes lipid hydroperoxide formation at each day. Equal variance
could be assumed for days 0, 3, and 7. At days 0, 3, and 7, particle type was found to
statistically affect amount of lipid hydroperoxides, with p values equal to 0.000, 0.000,
and 0.001 respectively. At days 0 and 3, all three liposomes were statistically different,
with the ethosomes containing the least hydroperoxides (Day 0: p<0.003, Day 3:
p<0.008) and the ultradeformable liposomes containing the most (Day 0: p<0.003, Day 3:
p<0.001). At day 7, the ethosomes and traditional liposomes were statistically similar
(p=0.282) and had the minimal amount of lipid hydroperoxides (p<0.005). At day 113,
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the one-way ANOVA showed that all three particle types were statistically similar
(p=0.518).
To determine which days are significantly different in lipid hydroperoxide amount
after initial post-fabrication, a one-way ANOVA with α=0.05 was performed on each
particle type. This showed that days statistically affected lipid hydroperoxide amount for
ethosomes, ultradeformable liposomes, and traditional liposomes (p= 0.000 for each
vesicle type). Equal variance could not be assumed for the ethosomes and traditional
liposomes. For the ethosomes, each day was statistically different with day 0 having the
minimal amount of lipid hydroperoxides (p<0.025). In the traditional liposomes, day 3
had the minimal amount of lipid hydroperoxides (p<0.028), followed by statistically
similar days 0 and 7 (p>0.999). Equal variance was assumed for the ultradeformable
liposomes (p= 0.546). Day 3 had minimal lipid hydroperoxides (p<0.020) followed by
day 0 (p<0.020).
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FIGURE 21 – Amount of Lipid Hydroperoxides for liposome at day 0 (A). Amount of
Lipid Hydroperoxides at days post-fabrication for Ethosomes (B), Ultradeformable
Liposomes (C), and Traditional Liposomes (D). * denotes statistically different.

2. Size Analysis
In order to determine the stability of the drug-loaded vesicles, the change in
particle diameter was analyzed over various time points using a one-way ANOVA
(α=0.05) and using a predetermined allowable change in size percentage from day 0. The
ANOVA found that particle size was not statistically significant between the differing
time points for the ethosomes (p=0.062) and ultradeformable liposomes (p=0.402).
However, post-fabrication day was found to be statistically significant for the traditional
liposomes (p=0.000); days 0 and 3 are statistically different from days 7, 14, and 30
(p<0.009 and p<0.001).
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FIGURE 22 –Mean diameter of Traditional Liposomes at various days post-fabrication. *
Denotes statistically different.

The percent changes in mean diameter size from day 0 in each particle type can
be seen in TABLE II. The ethosomes exceed their allowable percent change from day 0
of 34.5% in between days 3 and 7. The ultradeformable and traditional liposomes do not
exceed their predetermined percent change from day 0 of 22.5% and 32.8%, respectively.

TABLE II
PERCENT CHANGE IN PARTICLE MEAN DIAMETER FROM DAY 0
Percent change in Mean Diameter (%)
Days

Ethosomes
32.4

Ultradeformable
Liposomes
2.63

Traditional
Liposomes
5.65

0-3
0-7

74.5

6.80

20.9

0-14

75.7

6.21

22.5

7.84

20.7

0-30
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Denotes percent change is greater than predetermined limit.
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FIGURE 23 –Mean diameter of ethosomes at various days post-fabrication. † denotes
percent change from day 0 exceeds predetermined limit.
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FIGURE 24 –Mean diameter of ultradeformable liposomes at various days postfabrication.

In conclusion, the ethosomes initially have the least amount of lipid
hydroperoxides compared to the ultradeformable and traditional liposomes. However,
change in particle diameter from day 0 exceeds the predetermined limit during the day 3
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and 7 time points. The ultradeformable liposomes have the highest initial amount of lipid
hydroperoxides; however, the mean diameters do not significantly change from day 0 to
day 30. The traditional liposomes have a statistically significant change in diameter from
day 3 to day 7. Therefore, the ethosomes and traditional liposomes are stable until day 3
while the ultradeformable liposomes are stable until day 30.

C. Liposome Characterization Using SEM
An SEM image was used to ensure appropriate particle formation and
morphology. FIGURE 24A shows ethosome particle formation, EHT=2.00kV.
Ethosomes appear semi-spherical and vary in size. Figure 24B shows the ultradeformable
liposomes at an EHT=3.00kV. The ultradeformable liposomes exhibit a smooth and
spherical morphology with varying vesicle sizes. The traditional liposomes are shown in
Figure 24C at an EHT=2.00kV. They appear to have a semi-spherical formation with
varying sizes. The sizes appear to be similar to those established with the DLS.
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A

1 µm
B

1 µm
C

1 µm
FIGURE 25 – STEM images of (A) ethosomes, (B) ultradeformable liposomes, and (C)
traditional liposomes.
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D. Entrapment Efficiency

The ultracentrifugation method was used to determine curcumin entrapment
efficiency of each particle type. The three absorbance readings from one sample were
averaged together. These averages were used to run a one-way ANOVA post hoc Tukey
(α=0.05), which determined that vesicle type affects entrapment efficiency of curcumin
(p=0.008). Ethosomes had the highest entrapment efficiency of curcumin, 92.4% ±
4.69%, and was statistically different from the ultradeformable liposomes, 82.1% ±
5.27% (p=0.001). The traditional liposomes had an entrapment efficiency of 88.1% ±
3.17%. Traditional Liposomes were statistically similar to the ethosomes (p=0.189) and
the ultradeformable liposomes (p=0.061). These entrapment efficiencies yield a true
curcumin concentration in the ethosomes of 0.44 mg/ml, in the ultradeformable
liposomes of 0.39 mg/ml, and in the traditional liposomes of 0.42 mg/ml.
The entrapment efficiency of N-MPG was calculated theoretically, by taking the
percentage of inner vesicle volume over total volume of the sample. The ethosomes had
the highest entrapment efficiency of N-MPG of 3.08%. The ultradeformable liposomes
had the lowest N-MPG entrapment efficiency of 1.92%. The traditional liposomes had an
entrapment efficiency of 2.94%. The ethosomes having the highest entrapment efficiency
of curcumin and N-MPG was expected due to their larger hydrodynamic radius. These
entrapment efficiencies yield a theoretical N-MPG concentration in the ethosomes of
0.031 mg/ml, in the ultradeformable liposomes of 0.019 mg/ml, and in the traditional
liposomes of 0.029 mg/ml.
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TABLE III
ENTRAPMENT EFFICIENCY OF CURCUMIN AND N-MPG OF VESICLES
Particle Type

Actual Entrapment Efficiency of
curcumin mean ± standard
deviation (%)

Ethosomes
Ultradeformable
Liposomes
Traditional Liposomes

92.4 ± 4.69
82.1 ± 5.27*

Theoretical
Entrapment
Efficiency of N-MPG
(%)
3.08
1.92

88.1 ± 3.17

2.94

*denotes statistically different.

E. Skin Permeation
In order to quantify skin permeation of the vesicles, a modified Franz Diffusion
chamber was created using a 12 well plate and Transwell cell culture inserts to simulate
an apical and basal layer of skin. Pig skin was fixed to the cell culture insert and
treatments were placed on top of the skin. Absorbance measurements were taken from the
media below the insert inside the cell well using a NanoDrop spectrophotometer
(Thermo) at various time points. Most of the treatments were too similar to the control
PBS readings to detect differences, while the ultradeformable liposomes had extreme and
questionable variability. This could be due to machine insensitivity. Also, the surgical
glue used to secure the skin samples to the cell culture inserts could have clogged the
membrane pores, preventing permeation into the bottom chamber. Curcumin could have
also degraded, hindering absorption measurements.
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Skin Permeation: NanoDrop Readings (n=2)
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FIGURE 26 –Skin Permeation measurements taken with a NanoDrop.

Therefore, fluorescence was measured using a fluorometer (Turner Biosystems).
FIGURE 27 shows these results. Once again, this form of measurement was determined
unreliable because of the little difference from the PBS control treatment. Once again,
this could be due to machine insensitivity, clogging of pores, or curcumin degradation.

Skin Permeation: Fluorometer Readings (n=5)
Fluorescence (FSU)
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FIGURE 27 –Skin Permeation measurements taken with a Fluorometer.
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Quantifying the amount of vesicles permeating through the skin was proving
unsuccessful. Therefore, the amount of vesicles depositing in the skin was quantified. An
ultrasonic bath (Fisher Scientific) was used to release the vesicles from the skin.
Fluorescence readings were then taken. This was performed applying treatments for 2
and 24 hours. A one-way ANOVA post hoc Tukey (α=0.05) showed that particle type
significantly affects skin deposition at hours 2 and 24 (p=0.000 and p=0.000,
respectively). At hour 2, all particle types had statistically higher fluorescence then the
control PBS treatment (p<0.000) as expected. The particle treatment that exhibited the
highest skin deposition was the ethosomes (p=0.000), followed by the ultradeformable

Fluorescence (FSU)

Skin Deposition: Hour 2
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*

*
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Ultradeformable
Vesicles

Liposomes

Vesicle Type

FIGURE 28 –Skin Deposition of vesicles at hour 2. *denotes statistically different.
liposomes. The particle type that had the lowest fluorescence was the traditional
liposomes.

At hour 24, the control treatment, PBS, expectedly exhibited the least amount of
fluorescence and was statistically different from all other treatments (p<0.010). The
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particle treatment that had the highest fluorescence was the traditional liposomes, which
was also statistically similar to the ultradeformable liposomes (p=0.972). Out of the
particle types, the ethosomes had the lowest skin deposition at hour 24.
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FIGURE 29 –Skin Deposition of vesicles at hour 24. *denotes statistically different.

From the skin deposition results, one can conclude that the ethosomes penetrate
the skin faster, while the traditional liposomes and ultradeformable liposomes permeate
more slowly. Over time, the permeation of the ultradeformable liposomes and traditional
liposomes increases, exceeding the amount of ethosomes permeating.
In order to visualize the particles permeated into the skin, image analysis was
performed. An H&E stain was performed to visualize the skin layers and to determine the
approximate depth of each layer. Also, any differences in skin structure after the
treatments were examined.
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FIGURE 30 –H&E stained sections of treated pig skin, with magnified stratum corneum
of ethosomes and ultraformable liposomes
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The average length and standard deviation of the stratum corneum is 25.72 µm ± 9.02
µm. The average length and standard deviation of the epidermis is 61.25 µm ± 21.42 µm. The
only visual differences among the treated skin versus the PBS control skin can be seen in the
stratum corneum. In the ethosome and ultradeformable liposome treatments, the stratum corneum
appears more striated and porous. The depth of the skin layers were then used to analyze the
fluorescent images.

PBS

Curcumin
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Ethosomes

Ultradeformable Liposomes

Traditional Liposomes

FIGURE 31 –Bright field and GFP images of treated skin.
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The fluorescent images were taken using a confocal microscope and analyzed
using NIS Elements software. Sum intensity measurements were taken for each skin layer
for each treatment. A one-way ANOVA (α=0.05) found that particle type significantly
affected image sum intensity for the stratum corneum (p=0.001), the epidermis
(p=0.000), and the dermis (p=0.000). The curcumin control group was the group with the
minimal sum intensity for each skin layer. Equal variance could not be assumed for
comparing particle type in the stratum corneum layer (approximately 0-25 µm depth);
therefore, a Games-Howell post hoc was used. This analysis showed that the ethosome
treated skin had the highest sum intensity and were statistically different from the control
curcumin group (p=0.002). The ultradeformable liposomes were the next highest
treatment but were not statistically different from the curcumin control group (p=0.203)
or the traditional liposomes (0.372). The traditional liposomes were next and weren’t
statistically different from the control group (p=0.726) or ultradeformable liposomes.
Equal variance could be assumed for the epidermis and dermis layer; therefore, a
post hoc Tukey test was used to compare the particle types. In the epidermis layer
(approximately 25-86 µm depth), the traditional liposomes maximized the sum intensity
and were statistically different from the curcumin control (p=0.000). The next
maximizing treatment was the ethosomes which were statistically similar to the
traditional liposomes (p=0.149) and the curcumin control (p=0.072). The ultradeformable
liposomes were the least maximizing of the particle types and were statistically similar to
the control curcumin group (p=1.000). For the dermis layer (approximately 86 µm and
greater in depth), a post hoc Tukey showed that the sum intensity for the traditional
liposomes maximized the sum intensity and was statistically different from the curcumin
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control group (p=0.000). The ultradeformable liposomes were not statistically different
from the control group (p=0.350), nor were the ethosomes (p=0.057).

Image Fluorescence Analysis
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FIGURE 32 –Image fluorescence analysis. Skin permeation depth was obtained from
H&E depth measurements. * denotes statistically different.
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IV. CONCLUSIONS, DISCUSSION, & FUTURE WORK
In conclusion, three lipid vesicle formulations, traditional liposomes,
ultradeformable liposomes, and ethosomes, were designed for combined transdermal
delivery of two antioxidants, curcumin and N-MPG. All vesicles were less than 200 nm
in diameter and were characterized for stability, morphology, entrapment efficiency, and
transdermal delivery.
The ultradeformable and traditional liposomes were fabricated using the
mechanical-dispersion method. The ethosomes were fabricated using the cold method
and running the particles through a 0.2 µm sterile filter. These fabrication techniques
yielded vesicle sizes under the predetermined diameter limit of 200 nm.
The stability of the unloaded vesicles was determined using a PeroxiDetect Kit to
analyze the amount of lipid hydroperoxides. The particle type that inherently had the
minimal nano-moles of lipid hydroperoxides was the ethosomes, followed by the
traditional liposomes. However, from days 0 to 7, all of the lipid vesicles are under the
predetermined acceptable limit of 10 nmoles of lipid hydroperoxides. By day 113, all of
the lipid vesicles exceeded this limit. A potential issue with the results obtained from the
kit is that the phosphate in the lipid vesicle buffers could have interacted with the
solutions in the kit to cause higher absorbance readings. Therefore, the results are
representative of trends in lipid hydroperoxide formation. Also, the amount of lipid
hydroperoxides is expected to be much less with the presence of curcumin and N-MPG,
and hence more stable, because the antioxidants can quench their formation.
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The stability of the drug-loaded vesicles was also determined by measuring the
size of the particle types at various time points. The ultradeformable liposomes did not
statistically change in size or exceed the predetermined allowable amount of percent
change in size. At day 7, the traditional liposomes were statistically different in size from
day 0; however, they never exceeded their allowable percent change in size. The
ethosomes were not statistically different in size at measured time points; however, they
did exceed their allowable percent change in between days 3 and 7.
The morphology of each particle type was examined using SEM imaging. The
ultradeformable liposomes had the smoothest and most spherically shaped vesicles. The
ethosomes and the traditional liposomes were semi-spherically shaped, but were not as
smooth. The particle type that had the highest actual entrapment efficiency of curcumin
was the ethosomes; however, they were statistically similar to the traditional liposomes.
The ultradeformable liposomes had the lowest entrapment efficiency of curcumin and NMPG. The ethosomes, once again had the highest theoretical entrapment efficiency of NMPG. However, these theoretical entrapment efficiencies of N-MPG are still rather low.
Based on these results, the particles with the best stability and morphology are the
ultradeformable liposomes. The ethosomes had the best entrapment efficiency and were
statistically similar to the traditional liposomes. For the skin deposition studies, all
particle types had statistically higher fluorescence (α=0.05) than the PBS control. At hour
2, the ethosomes had the highest fluorescence and were statistically different from all
other treatment types. This indicates that the ethosomes have the quickest penetration into
the skin. At hour 24, the traditional liposomes had the highest fluorescence and were only
statistically similar to the ultradeformable liposomes. This indicates that over time, the
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traditional liposomes and ultradeformable liposomes increase in permeation. The
decrease in ethosome permeation could be due to particle breakdown because of their
relative instability. The pig skin is also potentially degrading, introducing pores, bacteria,
and other extraneous factors that could affect the results.
The image analysis showed that the ethosomes had the highest sum intensity in
the stratum corneum and were statistically different from the free curcumin control. In the
epidermis, the traditional liposomes had the highest sum intensity, were statistically
different from the free curcumin control, and also statistically similar to the ethosomes.
The traditional liposomes had the highest sum intensity in the dermis and were the only
treatment statistically different from the free curcumin control. The ethosomes have the
potential to be statistically different from the free curcumin control (p=0.057). Since this
image analysis was only performed with an n=1, increasing the number of replicates will
provide a better understanding of the potential of each treatment. However, these results
strongly indicate that the ethosomes and traditional liposomes permeate into and through
the stratum corneum.
For future work, the stability of the ethosomes and liposomes may need to be
increased by adding additional lipid soluble antioxidants. While curcumin is a lipid
soluble ROS scavenger, the location of the curcumin in the membrane bilayer is similar
to cholesterol. In this model, the phenolic hydroxyl groups of curcumin are close to the
water penetration space between adjacent phospholipids. The addition of alphatocopherol (Vitamin E), a known membrane antioxidant, could decrease ROS production
from the unsaturated fatty acids. Another approach is to use a base composition of
phospholipids that contains less unsaturated phospholipids. During fabrication, using a
68

homogenizer as opposed to a probe sonicator to decrease particle size could increase
stability as well. Probe sonication introduces ultrasound pulses into the solution, creating
excessive particle motion and high heat, leading to the formation of the degrading lipid
hydroperoxides. A homogenizer forces the particles through small pores, hence limiting
their size without the high temperatures.
Another future PeroxiDetect Assay performed on the particles with the lipids
extracted out of their buffer solutions may need to be completed to yield a more true
representation of vesicle stability. Also, more image analysis needs to be performed to
increase the sample size. The current sample size is just an n=1; therefore, the current
result is only a trend and qualitative assessment.
Ultimately, the particle treatments are going to be incorporated into a transdermal
patch, and future skin permeation studies will be performed. For applications requiring
short-term drug delivery of curcumin and N-MPG, such has a person needing immediate
relief from radiation poisoning, the ethosomes seem to be the best particle type. The
ethosomes had the quickest skin deposition and with further studies, may prove to reach
the deeper skin layers. Unless the stability of these particles are not improved upon, their
usefulness for more long-term applications, such as protection from extended radiation
exposure, appears to be limited. The particles that seem to be best for these types of
applications are the traditional liposomes. They are the particles that had the highest skin
deposition at hour 24 and the highest sum Intensity in the dermis skin layer.
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